Aspect Biosystems Announces $280 Million Partnership with the Government of Canada

Aspect Biosystems has announced a $280 million partnership with the Government of Canada to advance its platform for bioengineered cellular medicines targeting serious metabolic and endocrine diseases. The multi-year initiative is expected to support large-scale R&D, clinical translation, and manufacturing capacity in Canada, helping bring next-generation regenerative therapies closer to patients.

Read the full announcement and project details on Aspect’s website.